A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
By J. Shaughnessy, F. Zhan, B. Burington, Yongsheng Huang, S. Colla, I. Hanamura, J. Stewart, B. Kordsmeier, Christopher E Randolph, David R. Williams and 17 more. Blood, 2006
935 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/90a7d0e29967fb650cfbe382329d1ae4043e174b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
- Rafael A. Irizarry
- P. Richardson
- Grier P. Page
- T. Hideshima
- F. Martínez-Murillo
- Pan Du
- W. Kuehl
- Jean Thierry-Mieg
Citations in the corpus
- Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. (2007, methodology): “Microarray data from primary MM samples were obtained from http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE2658) (Shaughnessy et al., 2007; Zhan et al., 2006).”
- Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “Deletions of 17p and 1p, as well as loss of chromosome 13, are linked to poor prognosi”
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models (2010, background): “Gene expression profiling of highly purified bone marrow plasma cells was performed in newly diagnosed patients with M”